| Objective: To study the clinical effects of neurodynamic technique combined with mecobalamine on diabetic peripheral neuropathy. Methods: Ninety patients with diabetic peripheral neuropathy were randomly divided into experimental group and control group, 45 patients in each group. Patients in the control group were treated with mecobalamin, 0.5 mg each time, three times a day. In addition to the mecobalamine, patients in the experimental group were treated with neurodynamic technique. After 3 months we measured clinical efficacy rate, the simplified McGill scale, nerve conduction velocity (NCV) and the Mos 36-item Short Form Health Survey (SF-36). Results: After the treatment, the clinical efficacy rate in the experimental group was significantly higher than in the control group (91.1% vs.73.3%, P<0.05). The total scores of pain rating index (PRI), visual analogue scale (VAS) and present pain intensity (PPI) in the experimental group were significantly lower than in the control group (P<0.05). The motor NCV and sensory NCV in the experimental group were significantly faster than in the control group (P<0.05). The scores of the 8 domains and total score of SF-36 in the experimental group were significantly higher than in the control group. There were significant differences in the physical functioning, role-physical, bodily pain and role-emotional between the two groups (P<0.05), but there were no significant differences in the rest four domains and total score (P>0.05). Conclusion: Neurodynamic technique combined with mecobalamine for diabetic peripheral neuropathy is more effective, and worth promoting. |
